We’re covering everything from basic science all the way through to public health, including clinical work, translational work, clinical trials, and even computational work, and lots of omics studies, which are increasingly prevalent. when we’re really interested when we’re really interested involving early career researchers with the journal as reviewers, as editors, and certainly as authors. I'm Jennifer Sargent. I'm the Editor-in-Chief of Metabologia, the new journal from EASD. I've been working in scientific publishing and in the metabolism communities for over ten years. in the metabolism communities for over ten years. I'm the former Deputy Editor of Nature Medicine and a former senior editor at The Lancet. The motivation behind Metabologia, so EASD already has a brilliant journal, which is Diabetologia, of course, which is our big sister, but the field of diabetes is no longer in isolation, and it’s now increasingly recognised that diabetes, whether it’s type 1 or type 2, or even monogenic diabetes, these diseases do not occur alone. And there’s a lot of content that was being submitted to Diabetologia that falls just outside of the scope of that journal. And in recognition of more holistic patient care, the journal of Metabologia has been launched. We’ll be an online-only journal, and as soon as we start publishing, which by the time the first submissions get through peer review will probably be early 2026, potentially late 2025 if we’re really lucky. And what we aim to do, because it’s online only, there’ll be no official issues, but we’ll have our early content out soon, and then we aim to have regular content out every month or so. In terms of readers, we’re looking obviously at the EASD community, but also beyond that. So people who have been perhaps on the periphery of the diabetes community, who are doing research that is related to diabetes, but not necessarily on diabetes itself. So related comorbidity, lots of different aspects of diabetes that may not already be covered by Diabetologia. Even though obviously EASD is a European society, we’re a global journal, and that will be reflected when our editorial board is launched, that will certainly be reflected in the make up of that. The journal has been really quick to launch. We really wanted to get the submission site up and running for the EASD Congress in Vienna. We’ve managed to do that, and it’s been really great because I’ve been able to now have face-to-face talks about the journal with editors and people who are involved, going to be involved in the journal. Everyone should submit. So we’re very interested in obviously having established investigators submitting. We’re covering everything from basic science all the way through to public health, including clinical work, translational work, clinical trials, and even computational work, and lots of omics studies, which are increasingly prevalent. We’re really interested involving early career researchers with the journal as reviewers, as editors, and certainly as authors. For the first submission there’s no formal formatting requirement. It needs to have a title, and abstract, and you need to have your paper in the general IMRaD sections which would be your introduction, methods, results, and discussion. And if the paper is then continued, post peer review, then we’ll discuss formal formatting with you at that stage. You can go to metabologia.org and there’s a ‘Submit Here’ button which will take you straight to the online Springer Nature submission site. We're looking forward to getting a lot of good submissions. When we have become a more established journal, what we're hoping to do, I can’t guarantee this just yet, but we’re going to be exploring different ways of educational training within the publishing and peer review system. I obviously have a lot of knowledge about publishing, how to get your work published, how to write your papers, and I’d be happy to contribute those skills and knowledge to the EASD learning community. And I would also hope to involve early career researchers more in the peer review process and the editorial processes, how we select papers, how we curate the journal, how we commission reviews, but also how those are peer reviewed and what that general strategy behind publishing is. If we could follow in the legacy of Diabetologia, which has just had its 60th anniversary and we could be as long-lasting, as well recognised and as loved by and accepted by the EASD community, I would be really happy.